Office Action Predictor
Last updated: April 15, 2026
Application No. 18/019,270

CRYSTALINE FORMS OF AN O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITOR

Final Rejection §112§DP
Filed
Feb 02, 2023
Examiner
HEASLEY, MEGHAN CHRISTINE
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Biogen Ma INC.
OA Round
2 (Final)
76%
Grant Probability
Favorable
3-4
OA Rounds
3y 0m
To Grant
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allow Rate
83 granted / 109 resolved
+16.1% vs TC avg
Strong +34% interview lift
Without
With
+33.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
35 currently pending
Career history
144
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
33.1%
-6.9% vs TC avg
§102
18.6%
-21.4% vs TC avg
§112
27.3%
-12.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 109 resolved cases

Office Action

§112 §DP
Detailed Action Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims Claims 1, 2, 4, 5, 7, 12, 17, 20-21, 24-25, 32-34, 37-39, 41 and 45-46 are pending. Claims 1, 2, 5, 7, 24, 25, 32, 37, 38, 39, 45, and 46 are allowable. Claims 4, 20, 33-34, and 41 are objected to. Claims 12, 17, and 21 are rejected. Election/Restrictions Claim 1 is allowable. Claims 2, 4, 12, 17, 20, 21, 33, 34, 38, 39, and 41, previously withdrawn from consideration as a result of a restriction requirement, include all the limitations of an allowable claim. Pursuant to the procedures set forth in MPEP § 821.04(a), the restriction requirement between inventions, as set forth in the Office action mailed on 6/27/2025, is hereby withdrawn and claims 2, 4, 12, 17, 20, 21, 33, 34, 38, 39, and 41 are hereby rejoined and fully examined for patentability under 37 CFR 1.104. In view of the withdrawal of the restriction requirement, applicant(s) are advised that if any claim presented in a divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See In re Ziegler, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01. Response to Amendments/Arguments Applicant’s 1/6/2026 amendments have overcome all claim objections from the 10/6/2025 Office Action. Applicant’s 1/6/2026 remarks have overcome objections to specification from 10/6/2025 Office Action. Therefore, applicant remarks from 1/6/2026 will not be further addressed. Because of the rejoinder described supra, novel objections and rejections are presented below. Claim Objections Claim 4 is objected to because of the following informalities: Line 4, “hydrochloric salt Form” should read “hydrochloric salt form”; Line 5, “Phosphate salt Form” should read “phosphate salt form”. Claim 12 is objected to because of the following informalities: Line 15, “Hydrochloric” should read “hydrochloric”. Claim 17 is objected to because of the following informalities: Line 1, “Hydrochloric” should read “hydrochloric”. Claim 20 is objected to because of the following informalities: Line 1, “Phosphate” should read “phosphate”. Claim 21 is objected to because of the following informalities: Line 1, “Phosphate” should read “phosphate”. Claim 33 is objected to because of the following informalities: Line 3, “Hydrochloric” should read “hydrochloric”; Line 5, “Phosphate” should read “phosphate”. Claim 34 is objected to for depending from claim 33 and not remedying the deficiencies. Claim 41 is objected to because of the following informalities: Line 4, “Phosphate” should read “phosphate”; Line 5, “Tartrate” should read “tartrate”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 12, 17, and 21 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 12 recites the limitation "the compound" in line 2. There is insufficient antecedent basis for this limitation in the claim. Examiner recommends removing this limitation. Claim 12 recites the limitation "hydrochloric acid" in line 15. There is insufficient antecedent basis for this limitation in the claim. Examiner recommends changing the language to “hydrochloric salt” to be consistent with claim 4. Claim 17 recites the limitation "the compound" in line 1. There is insufficient antecedent basis for this limitation in the claim. Examiner recommends removing this limitation. Claim 17 recites the limitation "hydrochloric acid" in multiple locations. There is insufficient antecedent basis for this limitation in the claim. Examiner recommends changing the language to “hydrochloric salt” to be consistent with claim 4. Claim 21 recites the limitation "the compound" in line 1. There is insufficient antecedent basis for this limitation in the claim. Examiner recommends removing this limitation. Allowable Subject Matter Claims 1, 2, 5, 7, 24, 25, 32, 37, 38, 39, 45, and 46 are allowable. Conclusion Applicant’s amendments and a rejoinder necessitated the new ground(s) of rejection presented in this Office Action. Accordingly, THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEGHAN C HEASLEY whose telephone number is (571)270-0785. The examiner can normally be reached Monday - Friday 8:30-4:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy Clark can be reached on 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MEGHAN C HEASLEY/Examiner, Art Unit 1626 /KAMAL A SAEED/ Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Feb 02, 2023
Application Filed
Oct 02, 2025
Non-Final Rejection — §112, §DP
Jan 06, 2026
Response Filed
Feb 03, 2026
Examiner Interview (Telephonic)
Feb 09, 2026
Final Rejection — §112, §DP
Apr 10, 2026
Response after Non-Final Action

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600716
COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12582637
NOVEL TOPICAL FORMULATION FOR INTRADERMAL APPLICATION AND USES THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12577213
DEUTERATED 1,4-BENZODIAZEPINE-2,5-DIONE COMPOUND AND USE THEREOF
2y 5m to grant Granted Mar 17, 2026
Patent 12577246
INDOLINE COMPOUND
2y 5m to grant Granted Mar 17, 2026
Patent 12565490
INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+33.6%)
3y 0m
Median Time to Grant
Moderate
PTA Risk
Based on 109 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month